Yasin Hussain

Yasin Hussain

Auto-generated profile, based on publicly available information

Yasin Hussain

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
TSTayyab Shah
Tayyab Shah
AMArsalan Abu Much
Arsalan Abu Much
WBWayne Batchelor
Wayne Batchelor
CGCindy L. Grines
Cindy L. Grines
SBSuzanne J. Baron
Suzanne J. Baron
ALAlexandra J. Lansky
Alexandra J. Lansky

8 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MMMaiko Matsui
Maiko Matsui
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
MSMara Storto
Mara Storto
YHYasin Hussain
Yasin Hussain
AGAndrew Gregg
Andrew Gregg
GPGeoffrey S. Pitt
Geoffrey S. Pitt
Calcific aortic valve disease (CAVD) is heritable, as revealed by recent GWAS. While polymorphisms linked to increased expression of CACNA1C — encoding the Ca V 1.2 L-type voltage-gated Ca 2+ channel — and increased Ca 2+ signaling are associated with CAVD, whether increased Ca 2+ influx through the druggable Ca V 1.2 causes CAVD is unknown. We confirmed the association between increased Ca V 1.2 expression and CAVD in surgically removed aortic valves from patients. We extended our studies with a transgenic mouse model that mimics increased Ca V 1.2 expression within aortic valve interstitial cells (VICs). In young mice maintained on normal chow, we observed dystrophic valve lesions that mimic changes found in presymptomatic CAVD and showed activation of chondrogenic and osteogenic transcriptional regulators within these valve lesions. Chronic administration of verapamil, a Ca V 1.2 antagonist used clinically, slowed the progression of lesion development in vivo. Exploiting VIC cultures, we demonstrated that increased Ca 2+ influx through Ca V 1.2 drives signaling programs that lead to myofibroblast activation of VICs and upregulation of genes associated with aortic valve calcification. Our data support a causal role for Ca 2+ influx through Ca V 1.2 in CAVD and suggest that early treatment with Ca 2+ channel blockers is an effective therapeutic strategy.

28 July 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MIMahmoud Ismayl
Mahmoud Ismayl
YHYasin Hussain
Yasin Hussain
AAAhmed Aboeata
Ahmed Aboeata
RWRyan W. Walters
Ryan W. Walters
SNSrihari S. Naidu
Srihari S. Naidu
SAS. Elissa Altin
S. Elissa Altin

8 July 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
YHYasin Hussain
Yasin Hussain
SGSamantha Gaston
Samantha Gaston
JKJonathan Kluger
Jonathan Kluger
TSTayyab Shah
Tayyab Shah
YYYiping Yang
Yiping Yang
ALAlexandra Lansky
Alexandra Lansky

30 January 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
YHYasin Hussain
Yasin Hussain
KKKathleen E. Kearney
Kathleen E. Kearney
JAJ. Dawn Abbott
J. Dawn Abbott
DKDean J. Kereiakes
Dean J. Kereiakes
CMCarlo Di Mario
Carlo Di Mario
ALAlexandra J. Lansky
Alexandra J. Lansky
Coronary artery calcification increases the procedural complexity of percutaneous coronary intervention and is associated with worse outcomes, especially in women. Intravascular lithotripsy (IVL) has been demonstrated to be safe and effective for vessel preparation in severely calcified stenotic lesions before stent implantation. Sex-based outcomes of IVL-facilitated stenting have not been defined. We performed a patient-level pooled analysis of the 4 prospective, single-arm Disrupt CAD studies that evaluated the safety and efficacy of IVL-facilitated stenting. Patient baseline and procedural characteristics and clinical outcomes were examined based on sex. The primary safety end point was 30-day major adverse cardiovascular events, defined as the composite of cardiac death, myocardial infarction, or target vessel revascularization. The primary efficacy end point was procedural success, defined as stent delivery with residual in-stent stenosis ≤30% without in-hospital major adverse cardiovascular events. A total of 628 patients were included, of which 144 (22.9%) were women. Women were older (P < .001) and more likely to have hyperlipidemia (P = .03), renal insufficiency (P = .05), and prior myocardial infarction (P = .05). Women had smaller mean reference vessel diameter (2.7 ​ ± ​0.4 ​mm vs 3.0 ​ ± ​0.5 ​mm, P < .001), shorter lesion length (22.4 ​ ± ​10.3 ​mm vs 25.0 ​ ± ​11.7 ​mm, P = .01), and less side branch involvement (22.9% vs 32.4%, P = .03). Severe coronary calcification defined by angiography, stent delivery success, lesion predilatation, post-IVL dilatation, and poststent dilatation was similar between groups. There were no significant differences between women and men in the primary safety end point (8.3% vs 7.1%, P = .61; adjusted odds ratio 1.66; 95% confidence interval 0.78, 3.34; P = .17) or the primary efficacy end point (91.7% vs 92.6%, P = .72; adjusted odds ratio 0.58; 95% confidence interval 0.29, 1.24; P = .15). Post-IVL serious angiographic complications (flow-limiting dissection, perforation, abrupt closure, slow flow, no reflow) were similar for women and men (1.6% vs 2.3%, P = .75). Despite more comorbidities and smaller vessel size, IVL-facilitated stenting of severely calcified lesions achieves similar safety and efficacy in women and men.

1 July 2021 in EuroIntervention
Verified
Journal Article
Open access
YSYuichi Saito
Yuichi Saito
HKHenning Kelbæk
Henning Kelbæk
BXBo Xu
Bo Xu
YHYasin Hussain
Yasin Hussain
RARichard Anderson
Richard Anderson
ALAlexandra J. Lansky
Alexandra J. Lansky
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)